Semaphorin 3A upregulates FOXO 3a-dependent MelCAM expression leading to attenuation of breast tumor growth and angiogenesis

Oncogene

Volumn 34, Issue 12, 2015, Pages 1584-1595

  Mishra, R ^a   Thorat, D ^a   Soundararajan, G ^a   Pradhan, S J ^a,d   Chakraborty, G ^b   Lohite, K ^c   Karnik, S ^c   Kundu, G C ^a  

^a NATIONAL CENTRE FOR CELL SCIENCE   (India)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Grant Medical Foundation   (India)

^d INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CD146 ANTIGEN; FORKHEAD TRANSCRIPTION FACTOR; FOXO3 PROTEIN, HUMAN; MCAM PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, HUMAN; SEMA3A PROTEIN, HUMAN; SEMAPHORIN 3A;

ANIMAL; BREAST; BREAST TUMOR; CANCER TRANSPLANTATION; FEMALE; HUMAN; MCF 7 CELL LINE; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHOSPHORYLATION; SCID MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULARIZATION;

ANIMALS; ANTIGENS, CD146; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MCF-7 CELLS; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PTEN PHOSPHOHYDROLASE; SEMAPHORIN-3A; SIGNAL TRANSDUCTION;

EID: 84897967668     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.79     Document Type: Article

References (60)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. American Cancer Society. Cancer Facts & Figures 2013, American Cancer Society: Atlanta, GA, USA, 2013.
3. Kolodkin AL, Matthes DJ, Goodman CS. The semaphorin genes encode a family of transmembrane and secreted growth cone guidance molecules. Cell 1993; 75: 1389-1399.
4. Yazdani U, Terman JR. The semaphorins. Genome Biol 2006; 7: 211.
5. Serini G, Maione F, Giraudo E, Bussolino F. Semaphorins and tumor angiogenesis. Angiogenesis 2009; 12: 187-193.
6. Staton CA, Shaw LA, Valluru M, Hoh L, Koay I, Cross SS et al. Expression of class 3 semaphorins and their receptors in human breast neoplasia. Histopathology 2011; 59: 274-282.
7. Yacoub M, Coulon A, Celhay O, Irani J, Cussenot O, Fromont G. Differential expression of the semaphorin 3A pathway in prostatic cancer. Histopathology 2009; 55: 392-398.
8. He Z, Tessier-Lavigne M. Neuropilin is a receptor for the axonal chemorepellent Semaphorin III. Cell 1997; 90: 739-751.
9. Glauser DA, Schlegel W. The emerging role of FOXO transcription factors in pancreatic beta cells. J Endocrinol 2007; 193: 195-207.
10. Fu Z, Tindall DJ. FOXOs, cancer and regulation of apoptosis. Oncogene 2008; 27: 2312-2319.
11. Arden KC. FoxOs in tumor suppression and stem cell maintenance. Cell 2007; 128: 235-237.
12. Ramaswamy S, Nakamra N, Sansal I, Bergeron L, Sellers WR. A novel mechanism of gene regulation and tumor suppression by the transcription factor FKHR. Cancer Cell 2002; 2: 81-91.
13. Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M, Sellers WR. Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Bio 2000; 20: 8969-8982.
14. Dijkers PF, Birkenkamp KU, Lam EW, Thomas NS, Lammers JW, Koenderman L et al. FKHR-L1 can act as a critical effector of cell death induced by cytokine withdrawal: protein kinase-B enhanced cell survival through maintenance of mitochondrial integrity. J Cell Bio 2002; 156: 531-542.
15. Lehmann JM, Riethmüller G, Johnson JP. MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci USA 1989; 86: 9891-9895.
16. Xie S, Luca M, Huang S, Gutman M, Reich R, Johnson JP et al. Expression of MCAM/MUC18 by human melanoma cells leads to increased tumor growth and metastasis. Cancer Res 1997; 57: 2295-2303.
17. Shih LM, Hsu MY, Palazzo JP, Herlyn M. The cell-cell adhesion receptor Mel-CAM acts as a tumor suppressor in breast carcinoma. Am J Pathol 1997; 151: 745-751.
18. Shih IM. The role of CD146 (Mel-CAM) in biology and pathology. J Pathol 1999; 189: 4-11.
19. Chakraborty G, Rangaswami H, Jain S, Kundu GC. Hypoxia regulates cross-talk between Syk and Lck leading to breast cancer progression and angiogenesis. J Biol Chem 2006; 281: 11322-11331.
20. Satyamoorthy K, Muyrers J, Meier F, Patel D, Herlyn M. Mel-CAM-specific genetic suppressor elements inhibit melanoma growth and invasion through loss of gap junctional communication. Oncogene 2001; 20: 4676-4684.
21. Li G, Kalabis J, Xu X, Meier F, Oka M, Bogenrieder T et al. Reciprocal regulation of MelCAM and AKT in human melanoma. Oncogene 2003; 22: 6891-6899.
22. Vazquez F, Ramaswamy S, Nakamura N, Sellers WR. Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Bio 2000; 20: 5010-5018.
23. Torres J, Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteosomemediated degradation. J Biol Chem 2001; 276: 993-998.
24. Chadborn NH, Ahmed AI, Holt MR, Prinjha R, Dunn GA, Jones GE et al. PTEN couples Sema3A signalling to growth cone collapse. J Cell Sci 2006; 119: 951-957.
25. Bachelder RE, Lipscomb EA, Lin X, Wendt MA, Chadborn NH, Eickholt BJ et al. Competing autocrine pathways involving alternative neuropilin-1 ligands regulate chemotaxis of carcinoma cells. Cancer Res 2003; 63: 5230-5233.
26. Blanco-Aparicio C, Renner O, Leal JF, Carnero A. PTEN, more than the AKT pathway. Carcinogenesis 2007; 28: 1379-1386.
27. Castro-Rivera E, Ran S, Brekken RA, Minna JD. Semaphorin 3B inhibits the phosphatidylinositol 3-kinase/Akt pathway though neuropilin-1 in lung and breast cancer cells. Cancer Res 2008; 68: 8295-8303.
28. Rena G, Woods YL, Prescott AR, Peggie M, Unterman TG, Williams MR et al. Two novel phosphorylation sites on FKHR that are critical for its nuclear exclusion. EMBO J 2002; 21: 2263-2271.
29. Accili D, Arden KC. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 2004; 117: 421-426.
30. Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang F, Yang JY et al. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 2004; 117: 225-237.
31. Borkhardt A, Repp R, Hass OA, Leis T, Harbott J, Kreuder J et al. Cloning and characterization of AFX, the gene that fuses to MLL in acute leukemias with a t (X; 11)(q13;q23). Oncogene 1997; 14: 195-202.
32. Essers MA, de Vries-Smits LM, Barker N, Polderman PE, Burgering BM, Korswagen HC. Functional interaction between beta-catenin and FOXO in oxidative stress signaling. Science 2005; 308: 1181-1184.
33. Tang TT, Dowbenko D, Jackson A, Toney L, Lewin DA, Dent AL et al. The forkhead transcription factor AFX activates apoptosis by induction of the BCL-6 transcriptional repressor. J Biol Chem 2002; 277: 14255-14265.
34. Lu Y, Lin YZ, LaPushin R, Cuevas B, Fang X, Yu SX et al. The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene 1999; 18: 7034-7045.
35. Chakraborty G, Kumar S, Mishra R, Patil TV, Kundu GC. Semaphorin 3A suppresses tumor growth and metastasis in mice melanoma model. PLoS ONE 2012; 7: e33633. pone. 0033633.
36. Chakraborty G, Jain S, Kundu GC. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res 2008; 68: 152-161.
37. Miao HQ, Soker S, Feiner L, Alonso JL, Raper JA, Klagsbrun M. Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothelial cell motility: functional competition of collapsin-1 and vascular endothelial growth factor-165. J Cell Biol 1999; 146: 233-242.
38. Gabrovska PN, Smith RA, Tiang T, Weinstein SR, Haupt LM, Griffiths LR. Semaphorin-plexin signalling genes associated with human breast tumourigenesis. Gene 2011; 489: 63-69.
39. Nho RS, Kahm J. beta1-Integrin-collagen interaction suppresses FoxO3a by the coordination of Akt and PP2A. J Bio Chem 2010; 285: 14195-14209.
40. Liu JL, Sheng X, Hortobagyi ZK, Mao Z, Gallick GE, Yung WK. Nuclear PTENmediated growth suppression is independent of Akt down-regulation. Mol Cell Bio 2005; 25: 6211-6224.
41. Emerling BM, Weinberg F, Liu JL, Mak TW, Chandel NS. PTEN regulates p300-dependent hypoxia-inducible factor 1 transcriptional activity through Forkhead transcription factor 3a (FOXO3a). Proc Natl Acad Sci USA 2008; 105: 2622-2627.
42. Gil A, Andres-Pons A, Fernandez E, Valiente M, Torres J, Cervera J et al. Nuclear localization of PTEN by a Ran-dependent mechanism enhances apoptosis: Involvement of an N-terimnal nuclear localization domain and multiple nuclear exclusion motifs. Mol Bio Cell 2006; 17: 4002-4013.
43. Trotman LC, Wang X, Alimonti A, Chen Z, Teruya-Feldstein J, Yang H et al. Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 2007; 128: 141-156.
44. Paik JH, Kollipara R, Chu G, Ji H, Xiao Y, Ding Z et al. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 2007; 128: 309-323.
45. Li P, Lee H, Guo S, Unterman TG, Jenster G, Bai W. AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR. Mol Cell Biol 2003; 23: 104-118.
46. Seoane J, Le HV, Shen L, Anderson SA, Massague J. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 2004; 117: 211-223.
47. Bouchard C, Marquardt J, Bras A, Medema RH, Eilers M. Myc-induced proliferation and transformation require Akt-mediated phosphorylation of FoxO proteins. EMBO J 2004; 23: 2830-2840.
48. Potente M, Urbich C, Sasaki K, Hofmann WK, Heeschen C, Aicher A et al. Involvement of Foxo transcription factors in angiogenesis and postnatal neovascularisation. J Clin Invest 2005; 115: 2382-2392.
49. Wang L, Dutta SK, Kojima T, Xu X, Khosravi-Far R, Ekker SC et al. Neuropilin-1 modulates p53/caspases axis to promote endothelial cell survival. PLoS ONE 2007; 2: e1161.
50. Acevedo LM, Barillas S, Weis SM, Göthert JR, Cheresh DA. Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor. Blood 2008; 111: 2674-2680.
51. Nasarre C, Roth M, Jacob L, Roth L, Koncina E, Thien A et al. Peptide-based interference of the transmembrane domain of neuropilin-1 inhibits glioma growth in vivo. Oncogene 2010; 29: 2381-2392.
52. Yang L, Xie S, Jamaluddin MS, Altuwaijri S, Ni J, Kim E et al. Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells. J Biol Chem 2005; 280: 33558-33565.
53. Sinha S, Malonia SK, Mittal SP, Singh K, Kadreppa S, Kamat R et al. Coordinated regulation of p53 apoptotic targets BAX and PUMA by SMAR1 through an identical MR element. EMBO J 2010; 29: 830-842.
54. Rampalli S, Pavithra L, Bhatt A, Kundu TK, Chattopadhyay S. Tumor suppressor SMAR1 mediates cyclin D1 repression by recruitment of the SIN3/histone deacetylase 1 complex. Mol Cell Biol 2005; 25: 8415-8429.
55. Jain S, Chakraborty G, Raja R, Kale S, Kundu GC. Prostaglandin E2 regulates tumor angiogenesis in prostate cancer. Cancer Res 2008; 68: 7750-7759.
56. Raja R, Kale S, Thorat D, Soundararajan G, Lohite K, Mane A et al. Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1α-mediated VEGF-dependent angiogenesis. Oncogene 2014; 33: 2053-2064.
57. Kumar V, Behera R, Lohite K, Karnik S, Kundu GC. p38 kinase is crucial for osteopontin-induced furin expression that supports cervical cancer progression. Cancer Res 2010; 70: 10381-10391.
58. Sharma P, Kumar S, Kundu GC. Transcriptional regulation of human osteopontin promoter by histone deacetylase inhibitor, trichostatin A in cervical cancer cells. Mol Cancer 2010; 9: 178-189.
59. Vacca A, Scavelli C, Serini G, Di Pietro G, Cirulli T, Merchionne F et al. Loss of inhibitory semaphorin 3A (SEMA3A) autocrine loops in bone marrow endothelial cells of patients with multiple myeloma. Blood 2006; 108: 1661-1667.
60. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q et al. An online survival analysis tools to rapidly assess the effect of 22, 277 genes on breast cancer prognosis using microarray data of 1, 809 patients. Breast Cancer Res Treat 2010; 123: 725-731.